Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Targets Mid-2014 for Regulatory Submission of New MALDI Biotyper Libraries


NEW YORK (GenomeWeb) – Bruker said this week that it plans to make additional regulatory submissions for its MALDI Biotyper microbiology platform in the middle of this year.

In support of these planned submission, the company has launched a multi-site clinical trial for the instrument for validation of it for identification of rare Gram-negative bacteria, aerobic Gram-positive bacteria, yeasts, and anaerobic microorganisms.

In November of last year, Bruker received US Food and Drug Administration 510(k) clearance for the MALDI Biotyper and an initial library of more than 100 species of aerobic Gram-negative bacteria.

With the clearance, the Biotyper joined its primary competitor, BioMérieux's Vitek MS system, which received 510(k) clearance in August. The Vitek MS has maintained an advantage over the Biotyper in terms of breadth of coverage, however. While the Biotyper has FDA-cleared libraries only for aerobic Gram-negative bacteria, the Vitek MS has cleared libraries covering Gram-negative bacteria, Gram-positive bacteria, yeast, and anaerobes.

The planned regulatory submissions would help Bruker pull even in this regard. Bruker had originally planned to make these submissions in the first quarter of 2014.

Both the Biotyper and Vitek MS platforms identify microbes by matching the protein profiles of sample organisms generated via MALDI mass spec to profiles contained in a proprietary database. Compared to traditional biochemical methods of microbe detection, MALDI-based systems can offer significant improvements in speed, price, and accuracy.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.